clinical trial · NCT05862285
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
CancerIpatasertibTiragolumabAtezolizumabTiragolumab and AtezolizumabBevacizumabEntrectinibInavolisibDivarasib
brief summary
The purpose of this extension study is to provide continued treatment with Roche investigational medicinal product (IMP\[s\]) monotherapy or Roche IMP(s) combined with other agent(s) or comparator agent(s) for eligible participants with cancer who are still on study treatment at the time of roll-over from the parent study and who do not have access to the study treatment locally.
started
Jun 1, 2023
primary completion
Mar 1, 2033
completion
Mar 1, 2033
last updated
Jun 12, 2026
official title
An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol